IO Biotech, Inc.

The momentum for this stock is not very good. Tradey thinks it is not wise to invest in IO Biotech, Inc..

News

IO Biotech (NASDAQ:IOBT) Stock Rating Reaffirmed by HC Wainwright

Zolmax IO Biotech (NASDAQ:IOBT - Get Free Report)s stock had its "buy" rating reiterated by equities research analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They...\n more…

Morgan Stanley Lowers IO Biotech (NASDAQ:IOBT) Price Target to $4.00

Ticker Report IO Biotech (NASDAQ:IOBT - Get Free Report) had its price objective reduced by research analysts at Morgan Stanley from $7.00 to $4.00 in a research note issued on Tuesday, Benzinga reports. The firm...\n more…

IO Biotech (NASDAQ:IOBT) Given New $4.00 Price Target at Morgan Stanley

Zolmax IO Biotech (NASDAQ:IOBT - Free Report) had its target price reduced by Morgan Stanley from $7.00 to $4.00 in a research note issued to investors on Tuesday morning, Benzinga reports. They currently...\n more…

IO Biotech price target lowered by $3 at Morgan Stanley, here's why

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

IO Biotech says IDMC recommends continuation of IO102-IO103 trial

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

Globe Newswire - Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that the trial continue without modifications- No new safety...\n more…